Kornimate/medical-research-clean huggingface dataset:
quality of life after treatment for bladder cancer: the bladder cancer survivorship study

Conditions: Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8

Summary: this study evaluates the effect of bladder cancer treatment on quality of life.

primary objectives: i. to compare general and disease-specific quality of life outcomes at 6, 12, 24, and 36 months after treatment for localized bladder cancer using the promis-29 and the bladder cancer index (bci) respectively. ii. to identify patient level characteristics that may influence quality of life outcomes after treatment for localized bladder cancer. outline: this is an observational study. patients complete surveys and also have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * have pathologically confirmed, clinically localized, bladder cancer * be willing to complete a survey in english before starting definitive treatment (surgery or radiation); * able to give consent. exclusion criteria: * does not meet inclusion criteria
efficacy and tolerability of peg-only laxative for fecal impaction and chronic constipation in children

Conditions: Constipation; Faecal Impaction

Summary: the aim of this study is to compare the efficacy, tolerability, acceptance and compliance of a peg-only formulation compared to a reference peg-el formulation in resolving faecal impaction and in the treatment of chronic constipation

constipation is a very common complaint in childhood. inadequate daily fiber intake, insufficient fluid intake, and withholding behavior are considered as factors leading to constipation. painful defecation is considered a common trigger to faecal retention wich leads to reabsorption of fluids and increase in the size and consistency of stools. it is often necessary to use laxative therapy to achieve comfortable defecation. peg-based laxatives are considered today the gold standard for treatment of constipation in children. peg formulations differ for composition in inactive ingredients which may have an impact on acceptance, compliance and adherence to treatment.

Eligibility criteria:
inclusion criteria: * out-patients children with diagnosis of functional constipation or have faecal impaction on medical history and physical examination exclusion criteria: * children with organic causes for defecation disorders, such as hirschsprung disease, spina bifid, hypothyroidism, or other metabolic or renal abnormalities; * children receiving medication influencing gastrointestinal motility; * children with suspected gastrointestinal obstruction or stenosis

Keywords: chronic constipation faecal impaction peg-only laxative
single-cell sequencing of blf to guide the treatment of radiation pneumonitis or immune checkpoint inhibitor pneumonitis

Conditions: Pneumonitis

Summary: a multicenter, exploratory clinical research, to map the radiation or immune checkpoint inhibitor pneumonitis in patients with alveolar lavage single-celled map. find out the pathogenesis and prevention strategies of radiation or immune checkpoint inhibitor pneumonitis. specific treatment is given based on the recommendation of the treatment guidelines for radiation or immune checkpoint inhibitor pneumonitis and the results of single cell sequencing, which will become a new technology for clinical application.

this study is a multicenter, exploratory clinical research, to map the radiation or immune checkpoint inhibitor pneumonitis in patients with alveolar lavage single-celled map. find out the pathogenesis and prevention strategies of radiation or immune checkpoint inhibitor pneumonitis. specific treatment is given based on the recommendation of the treatment guidelines for radiation or immune checkpoint inhibitor pneumonitis and the results of single cell sequencing, which will become a new technology for clinical application.

Eligibility criteria:
inclusion criteria: 1. informed consent has been signed, and according to the judgment of the investigator, the patient can comply with the study protocol and sign the written informed consent; 2. nsclc patients who have been clinically diagnosed with rp or cip after histopathologically confirmed radiotherapy or immunocheckpoint inhibitor treatment and have not received glucocorticoid or other drugs. 3. ≥18 years old, less than 75 years old; 4. ecog ps score 0-3 in the eastern tumor collaboration group; 5. patients without contraindications to alveolar lavage; exclusion criteria: 1. poor patient compliance and violation of test regulations; 2. liver and kidney dysfunction, such as myocardial infarction, angina pectoris, liver transaminase significantly increased; 3. had any medical condition requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to enrollment; 4. severe infection occurred within 4 weeks prior to enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia; 5. severe chronic or active infections (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic treatment within 14 days prior to enrollment; 6. untreated patients with chronic hepatitis b, hbv carriers with hbv dna≥ 500 iu/ml, or patients with active hepatitis c virus (hcv) should be excluded. note: non-active hepatitis b, surface antigen (hbsag) carriers, treated and stable hepatitis b carriers (hbv dna \& lt; 500 iu/ml), patients with cured hepatitis c could be enrolled; 7. known history of hiv infection; 8. received any other investigational drug or participated in any other clinical trial within 28 days.

Keywords: single-cell sequencing radiation pneumonitis immune checkpoint inhibitor pneumonitis bronchoalveolar lavage fluid
sevoflurane inhalation in cardiac arrest resuscitated patients treated with therapeutic hypothermia

Conditions: Cardiac Arrest; Therapeutic Hypothermia

Summary: studying the feasibility of an initial sedation with inhalated sevoflurane during therapeutic hypothermia of cardiac arrests resuscitated patients.

prospective clinical study in icu with ventilated patients sedated with sevoflurane using the mirus® and anaconda® , establishing the feasibility of an initial sedation of patients resuscitated from cardiac arrest and treated with therapeutic hypothermia.

Eligibility criteria:
inclusion criteria: * -adult patients ventilated requiring therapeutic hypothermia in icu * stable respiratory and hemodynamic conditions * epinephrine and norepinephrine infusion rate \< 1,5 g/kg/min * consent of patients or family * arterial line * patients resuscitated after cardiac arrest * no flow \< 10 min * low flow \< 20 min * neutropenia \< 1 g/l * post traumatic cardiac arrest * contraindication of halogenated anesthesics * extra corporeal life support or intra aortic balloon pump exclusion criteria: * -pregnant woman * hemodynamic instability * brain death defined by the disappearance of brain stem reflexes

Keywords: cardiac arrest therapeutic hypothermia sevoflurane sedation patient resuscitated from cardiac arrest requiring sedation adult patients patient covered by french health care system
68ga-p16-093 pet/ct imaging in glioma patients

Conditions: Glioma

Summary: psma is highly expressed on the cell surface of the microvasculature of several solid tumors, including glioma. this makes it a potentially imaging target for the detection and grading of gliomas. this pilot study was designed to evaluate the diagnostic performance of 68ga-p16-093, a novel radiopharmaceutical targeting psma, which was compared with mri in the same group of glioma patients.

glioma is the most common primary malignant brain tumor which can be divided into four grades according to different histopathological and molecular biological characteristics.among them, glioblastoma is one of the most common types of glioma in adults (about 55%). it belongs to who grade iv high-grade glioma, with a high recurrence rate, poor prognosis, and a 5-year survival rate of less than 10%. prostate-specific membrane antigen (psma), as known as folate hydrolase i or glutamate carboxypeptidase ii, is overexpressed on the cells of prostatic adenocarcinoma. however, psma is also expressed by tumor cells or neovascular endothelial cells of various solid neoplasms, such as glioma. therefore, psma may be an ideal target for the diagnosis of glioma. 68ga-p16-093, a novel radiopharmaceutical targeting psma, with the urea fragment of a conjugate that employs the hbed-cc chelator for labeling with 68ga(iii). the hbed-based chelating ligand binds the 68ga3+ ion with high affinity in a pseudo-octahedral n2o4 coordination sphere by its two phenolate o, two amino-acetate carboxylate o, and two amino n donor atoms. this pilot study was designed to evaluate the diagnostic performance of 68ga-p16-093 in the same group of glioma patients, compared with mri.

Eligibility criteria:
inclusion criteria: * glioma patients highly suggested by mri or histologically confirmed; * 68ga-p16-093 pet/ct and mri within two weeks; * signed written consent. exclusion criteria: * known allergy against psma; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
performance and efficacy of the cardiacsense1 for detection of atrial fibrillation

Conditions: Atrium; Fibrillation

Summary: a prospective, open, multi-center, controlled study to evaluate the safety, performance and efficacy of the cardiacsense1 for detection of atrial fibrillation. the clinical study is intended to establish the efficacy and safety of the cardiacsense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (a-fib) based on a comparison to a control device, which is an off-the-shelf cleared holter ecg device

the clinical study is intended to establish the efficacy and safety of the cardiacsense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (a-fib). study design as as follows: 100 subjects, 50 (at least 30% of each gender) with a-fib and 50 without (at least 30% of each gender). all subjects will be measured during at least 24 hours. primary endpoint - a-fib detection control: holter device will be the reference for ppg analysis, each one hour will be considered as an event: if a-fib is present for more than accumulated 5 minutes in that specific hour then it shall be considered an "a-fib hour" if a-fib was present for less than accumulated 5 minutes then it shall be considered a "non-a-fib hour". for ecg analysis, each measurement of between 1-3 minutes will be considered an event. if a-fib is present at that specific measurement, then it shall be considered an "a-fib event" if a-fib was not present at that specific measurement, then it shall be considered a "non-a-fib hour". sensitivity (true positive) is defined as the percentage of holter defined "a-fib hours"/"a-fib event" found by ppg/ecg. the asked sensitivity is 90%. specificity (true negative) is defined as the percentage of holter defined "non-a-fib hours"/"a-fib event" found by ppg/ecg. the required specificity is 90%.

Eligibility criteria:
inclusion criteria: * age of eighteen (18) year and above * diagnosed with atrial fibrilation (permanent of persistent), or healthy participants able to and willing to sign the informed consent form for control group-no known cardiac problems exclusion criteria: * subjects who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the subject's participation in this study. * subjects with low perfusion as indicated by the watch * women who are pregnant or breastfeeding
a study to evaluate azd2693 in participants who are carriers of the pnpla3 148m risk allele with non-cirrhotic non-alcoholic steatohepatitis with fibrosis

Conditions: Nonalcoholic Steatohepatitis

Summary: a study to evaluate the efficacy, safety and tolerability of azd2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the pnpla3 148m risk allele


Eligibility criteria:
key inclusion criteria : participants are eligible to be included in the study only if all the following criteria apply: age 1. participant must be 18 to 75 years of age (inclusive) at the time of signing the informed consent. type of participant and disease characteristics 2. participants who are carriers for the pnpla3 rs738409 148m risk allele. 3. participants with histological evidence of nash based on central pathologist evaluation of a liver biopsy obtained up to 6 months before randomisation, or during screening, fulfilling both criteria: 1. definitive nash with nas ≥ 4 with ≥ 1 in each component (ie, steatosis, lobular inflammation, and ballooning). 1. presence of fibrosis stage f2 or f3 according to the nash crn fibrosis staging system based on central pathologist evaluation. key exclusion criteria : participants are excluded from the study if any of the following criteria apply: medical conditions 1. liver disease of other aetiologies (eg, alcoholic steatohepatitis; drug-induced, viral or autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; hemochromatosis; alpha-1 antitrypsin deficiency; wilson's disease) 2. history of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding. 3. historical persistent or pre-existing renal disease marked by egfr \< 40 ml/min/1.73 m2 (as defined by kidney disease improving global outcomes guidelines). 4. confirmed platelet count outside the normal range at the screening visit. 5. any of the following confirmed at the screening visit: 1. alt \> 5.0 × uln 2. tbl \> 1.5 mg/dl (tbl \> 1.5 mg/dl is allowed if conjugated bilirubin is \< 1.5 × uln) 3. inr \> 1.3 4. alp \> 1.5 × uln (unless the alp elevation is not from hepatic origin as determined by a bone-specific alp)

Keywords: nonalcoholic steatohepatitis nash fatty liver disease non alcoholic fatty liver liver fibrosis pnpla3 148m risk allele non cirrhotic
efficacy and safety of hgxjt in bone metastatic nsclc patients

Conditions: Non-small Cell Lung Cancer

Summary: this is a double-blind, randomized controlled study evaluating the efficacy and safety of hgxjt in combination with ici-based standard treatment in lung cancer patients with bone metastases. enrolled participates will randomly receive hgxjt or placebo during the first 4-6 cycles of ici-based standard treatment.


Eligibility criteria:
inclusion criteria: 1. patients with non-small cell lung cancer diagnosed by histopathology or cytopathology. 2. presence of bone metastases. 3. egfr/alk gene wild type. 4. no prior treatment with pd-1 inhibitors (combination or monotherapy) 5. those who have not received prior antitumor therapy or have not received further antitumor therapy after failure of first-line antitumor therapy. 6. ps score (ecog) ≤ 2 points 7. normal hepatic and renal function. normal hepatic function: total serum bilirubin level ≤ 1.5 times of the upper limit of normal value(uln), serum serum aspartate aminotransferase(ast) \& alanine aminotransferase(alt) ≤ 2.5 times uln normal renal function: serum creatinine ≤ 1.5 mg/dl (133 μmol/l) and/or creatinine clearance ≥ 60 ml/min. 8. presence of at least one assessable lesion. 9. signed informed consent, patient willing to accept this regimen, able to adhere to the medication, and good compliance. exclusion criteria: 1. unable to complete the baseline assessment form 2. combination of other serious illnesses, including uncontrolled active infection, severe electrolyte disturbances, and significant bleeding tendencies. 3. pregnant or lactating women. 4. combined autoimmune diseases, hematologic disorders, or long-term use of hormones or immunosuppressive drugs. 5. combination of other uncontrolled tumors. 6. combination of severe brain or mental illness that affects the patient's ability to self-report. 7. combined organ transplant history (including bone marrow autotransplantation and peripheral stem cell transplantation). 8. those who are legally incompetent and whose medical or ethical reasons affect the continuation of the research.

Keywords: non-small cell lung cancer bone metastatic immune checkpoint inhibitors chinese formula efficacy safety
assessing the effects of air-cooling on capillary malformations

Conditions: Capillary Malformation; Laser; Skin Cooling

Summary: the purpose of this observational study is to ascertain the effects of cutaneous air cooling on vessel diameter within capillary malformations (cm).

capillary malformation (cm) is the most common vascular malformation occurring in approximately 0.3% of all newborn. the standard treatment for facial or aesthetically sensitive cm's is flashlamp pulsed dye laser. skin cooling prior to laser treatment of cms is standard practice within our department. the effects of skin cooling on the vasculature within cms are poorly understood. previous studies by our department have shown that raising ambient temperature increases cm vessel size. it has been postulated that by increasing cm vessel size, it may also increase the effectiveness of treatment. we hypothesize that cooling the skin during laser treatment may cause vasconstriction of the superficial vessels within the cm. this may have an impact on treatment success.

Eligibility criteria:
inclusion criteria: * adult more than 16 years of age * patient diagnosed with capillary malformation exclusion criteria: * patients less than 16 years of age

Keywords: skin disease capillary malformation laser therapy
lanthanum versus calcium carbonate for vascular abnormalities in patients with ckd and hyperphosphatemia

Conditions: Renal Insufficiency, Chronic; Hyperphosphatemia; Bone Diseases, Metabolic

Summary: the purpose of this study is to compare the effect of lanthanum carbonate and calcium carbonate on the progression of coronary calcification and vascular endothelial dysfunction.


Eligibility criteria:
inclusion criteria: * hyperphosphatemia (for patients without calcium carbonate, ≥4.5 mg/dl) (for patients with calcium carbonate, ≥4.0 mg/dl) * with written informed consent exclusion criteria: * history of cardiac surgery * with coronary artery stent * polycystic kidney disease * hypothyroidism * on treatment with lanthanum carbonate * history of admission within 3 months * history of ileus * severe liver dysfunction * severe gastrointestinal dysfunction * allergy to lanthanum carbonate or calcium carbonate * pregnant or breastfeeding women * judged as ineligible by the investigator

Keywords: lanthanum calcium carbonate vascular calcification
omega-study: effect of omega 3-fatty acids on the reduction of sudden cardiac death after myocardial infarction

Conditions: Myocardial Infarction

Summary: cardiovascular disease (cvd) is the leading cause of death in north america and europe. the major cause of cvd is atherosclerosis like coronary artery disease (cad). the results of recent trials hint that the course of cad may be positively influenced by an increased intake of omega 3-fatty acids. the omega-trial analyses this effect in subjects who suffered an acute myocardial infarction. they are divided into two groups, both receiving standard post-infarction therapy. the subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Eligibility criteria:
inclusion criteria: * myocardial infarction 3-14 days before randomisation (stemi and nstemi) * ability to take ω-3-fae or olive oil without risk * informed consent exclusion criteria: * premenopausal women who are not surgically sterile, who are pregnant or nursing, who are of child-bearing potential and are not practising acceptable means of birth control (pregnancy testing required before randomisation) * known hypersensitivity to study medication * dislike of fish oil * haemorrhagic diathesis * unwillingness to discontinue other medications containing fish oil * legal incapacity * history of drug or alcohol abuse within 6 months * any investigational therapy within one month of signing informed consent form

Keywords: myocardial infarction omega 3-fatty acids
a stepwise strategy utilizing buprenorphine and methadone

Conditions: Heroin Dependence

Summary: the objective of this study is to compare optimally given methadone maintenance treatment (mmt) for heroin dependence with a novel, sequential strategy, where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient.

the objective of this study is to compare optimally given methadone maintenance treatment (mmt) for heroin dependence with a novel, sequential strategy (step), where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient. for this purpose, 96 subjects at two centers (uppsala and stockholm) are randomized to mmt or step and followed for 6 months. retention in treatment is the primary outcome. secondary outcomes in completers are proportion urine samples free of illicit opiates on app. twice weekly sampling, and problem severity as measured by a semistructured interview, the addiction severity index (asi) at baseline and after 3 and 6 months.

Eligibility criteria:
inclusion criteria: * heroin dependence according to dsm iv \> 1year * age \> 20 years * acceptance of the stated treatment principles. exclusion criteria: * severe psychiatric illness such as dementia or psychosis compromising the patient's ability to provide informed consent * other clinically significant psychiatric illness unless stable under treatment * severe medical condition such as advanced lung disease, unstable cardiovascular disease, severe liver disease * other clinically significant medical condition unless stable under treatment * treatment with anti-seizure drugs or disulfiram * pregnancy or intent to become pregnant within the next year * ongoing nursing * patients involuntarily discharged from a methadone or buprenorphine maintenance program within the last 3 months not eligible.

Keywords: heroin dependence methadone buprenorphine contingency management relapse prevention
post transplant cyclophosphamide in matched unrelated donor stem cell transplantation for hematological malignancies

Conditions: Bone Marrow Transplant Complications; Graft Versus Host Disease; Infection Viral; Engraft Failure; Immunologic Suppression

Summary: this study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic gvhd. thirty patients will receive cyclophosphamide while twenty patients will receive antihuman t-lymphocyte immune globulin (atg).


Eligibility criteria:
inclusion criteria: * men and women of any age * indication for an hsct without matched sibling donor * have a matched unrelated donor (hla 10 x 10 or 9 x 10) * hematological malignancy exclusion criteria: * acute leukemias not in complete response (that is \> 5% blast in the bone marrow) * chemorefractory lymphoproliferative disease * active uncontrolled infection * hct-ci \> 3 * severe organic disfunction (heart ejection fraction \< 45%, glomerular filtration rate \< 50 ml.hour, pulmonary dlco \< 50%) * previous allogeneic bone marrow transplantation * contraindication to cyclophosphamide or atg

Keywords: bone marrow transplantation hematological malignancies post-cy